(a) Measuring device; (b) Measuring method. حسب Chenhao Li (822769)

"…Although increasing SHMP content improved the early strength, it led to a decrease in later strength, with the maximum late strength observed at 2% SHMP. …"

Participants demographic data. حسب Gabriela Garcia (119921)

"…A decrease in mean erector spinae activity was observed in males only. …"

(a) Molds; (b) Samples; (c)(d) Test devices. حسب Chenhao Li (822769)

"…Although increasing SHMP content improved the early strength, it led to a decrease in later strength, with the maximum late strength observed at 2% SHMP. …"

Image1_Clinical characteristics and early identification of augmented renal clearance in PICU patients with severe sepsis associated with MRSA infection.pdf حسب Haonan Wang (667218)

"…</p>Conclusion<p>ARC is a phenomenon significantly underestimated in pediatric patients with severe sepsis associated with MRSA infection, which can affect 74.9% of these patients and affects the process of anti-infection treatment and clinical outcomes. …"

Data Sheet 1_Detection of hemodynamic changes in a porcine lipopolysaccharide model of systemic inflammation using dynamic light scattering measurements of the microcirculation.pdf حسب Louwrina H. te Nijenhuis (20762678)

"…Both intervention groups showed a Hurst exponent decrease centrally at T2 and peripherally already at T1.…"

Dexmedetomidine pretreatment alleviates brain injury in middle cerebral artery occlusion (MCAO) model rats by activating PI3K/AKT/NF-κB signaling pathway حسب Wei Gao (2085)

"…DEX pretreatment reversed the effects of MCAO as evidenced by decrease in protein expression levels of TNF-α and IL-6 associated with elevated protein expression levels of PI3K/AKT/NF-κB signaling pathway. …"

Supplementary Material for: Preliminary efficacy, tolerability, and safety analysis of Darolutamide for metastatic castration‑resistant prostate cancer: a single-center, open-label... حسب Yu J. (3610580)

"…The median time to PSA50 in the Darolutamide group was 1.5 months (95%CI 0.2619- 0.9545), significantly lower than that in the placebo group (3.0 months [95%CI 1.048- 3.818], p= 0.0259); The median time to PSA90 in the experimental group was 4 months (95%CI 0.3094- 1.437), 2 months shorter than that in the placebo group (6.0 months [95%CI 0.6961- 3.232]).With the median follow-up of 6 months, , the median decrease in serum PSA was -81.8% (range -60.4 to -99.9%) in the Darolutamide group and -69.4% (range -50.3 to -89.6%) in the placebo group. …"

Image 3_Impact of HCV cure on systemic inflammation and bone density, quality, and turnover.pdf حسب Christina K. Psomas (15374521)

"…Treatment with direct-acting antivirals (DAA) eradicates HCV and decreases inflammation, but the impact on bone parameters has not been studied.…"

Image 2_Impact of HCV cure on systemic inflammation and bone density, quality, and turnover.pdf حسب Christina K. Psomas (15374521)

"…Treatment with direct-acting antivirals (DAA) eradicates HCV and decreases inflammation, but the impact on bone parameters has not been studied.…"

Image 1_Impact of HCV cure on systemic inflammation and bone density, quality, and turnover.pdf حسب Christina K. Psomas (15374521)

"…Treatment with direct-acting antivirals (DAA) eradicates HCV and decreases inflammation, but the impact on bone parameters has not been studied.…"

Image 4_Impact of HCV cure on systemic inflammation and bone density, quality, and turnover.pdf حسب Christina K. Psomas (15374521)

"…Treatment with direct-acting antivirals (DAA) eradicates HCV and decreases inflammation, but the impact on bone parameters has not been studied.…"

Table 1_Impact of HCV cure on systemic inflammation and bone density, quality, and turnover.pdf حسب Christina K. Psomas (15374521)

"…Treatment with direct-acting antivirals (DAA) eradicates HCV and decreases inflammation, but the impact on bone parameters has not been studied.…"

Image 4_Low miR-936-mediated upregulation of Pim-3 drives sorafenib resistance in liver cancer through ferroptosis inhibition by activating the ANKRD18A/Src/NRF2 pathway.jpeg حسب Xiao Li (107004)

"…MiR-936 overexpression and GV102-Pim-3-shRNA significantly attenuated the activity of the ANKRD18A/Src/NRF2 pathway to decrease the expression of Ankyrin repeat domain-containing protein 18A (ANKRD18A), Src, and Nuclear factor (erythroid-derived 2)-like 2 (NRF2), especially decreasing NRF2 nuclear retention and transcriptional activity. …"

Table 1_Variations in vitamin D status among Chinese children aged 1–6 years during the COVID-19 pandemic.xlsx حسب Yongfeng Qiao (3354326)

"…The average of 25(OH)D concentration were 38.2 ± 9.8 ng/ml, significantly varying by age and season. 25(OH)D concentrations decreased with age, from 42.3 ± 8.8 ng/ml at 1-year-olds to 37.4 ± 8.2 ng/ml at 2-year-olds, and further to 30.2 ± 8.1 ng/ml at 3 to 6-year-olds. …"

Image 2_Low miR-936-mediated upregulation of Pim-3 drives sorafenib resistance in liver cancer through ferroptosis inhibition by activating the ANKRD18A/Src/NRF2 pathway.jpeg حسب Xiao Li (107004)

"…MiR-936 overexpression and GV102-Pim-3-shRNA significantly attenuated the activity of the ANKRD18A/Src/NRF2 pathway to decrease the expression of Ankyrin repeat domain-containing protein 18A (ANKRD18A), Src, and Nuclear factor (erythroid-derived 2)-like 2 (NRF2), especially decreasing NRF2 nuclear retention and transcriptional activity. …"

Image 1_Low miR-936-mediated upregulation of Pim-3 drives sorafenib resistance in liver cancer through ferroptosis inhibition by activating the ANKRD18A/Src/NRF2 pathway.jpeg حسب Xiao Li (107004)

"…MiR-936 overexpression and GV102-Pim-3-shRNA significantly attenuated the activity of the ANKRD18A/Src/NRF2 pathway to decrease the expression of Ankyrin repeat domain-containing protein 18A (ANKRD18A), Src, and Nuclear factor (erythroid-derived 2)-like 2 (NRF2), especially decreasing NRF2 nuclear retention and transcriptional activity. …"

Image 5_Low miR-936-mediated upregulation of Pim-3 drives sorafenib resistance in liver cancer through ferroptosis inhibition by activating the ANKRD18A/Src/NRF2 pathway.jpeg حسب Xiao Li (107004)

"…MiR-936 overexpression and GV102-Pim-3-shRNA significantly attenuated the activity of the ANKRD18A/Src/NRF2 pathway to decrease the expression of Ankyrin repeat domain-containing protein 18A (ANKRD18A), Src, and Nuclear factor (erythroid-derived 2)-like 2 (NRF2), especially decreasing NRF2 nuclear retention and transcriptional activity. …"

Table 1_Low miR-936-mediated upregulation of Pim-3 drives sorafenib resistance in liver cancer through ferroptosis inhibition by activating the ANKRD18A/Src/NRF2 pathway.docx حسب Xiao Li (107004)

"…MiR-936 overexpression and GV102-Pim-3-shRNA significantly attenuated the activity of the ANKRD18A/Src/NRF2 pathway to decrease the expression of Ankyrin repeat domain-containing protein 18A (ANKRD18A), Src, and Nuclear factor (erythroid-derived 2)-like 2 (NRF2), especially decreasing NRF2 nuclear retention and transcriptional activity. …"

Image 3_Low miR-936-mediated upregulation of Pim-3 drives sorafenib resistance in liver cancer through ferroptosis inhibition by activating the ANKRD18A/Src/NRF2 pathway.jpeg حسب Xiao Li (107004)

"…MiR-936 overexpression and GV102-Pim-3-shRNA significantly attenuated the activity of the ANKRD18A/Src/NRF2 pathway to decrease the expression of Ankyrin repeat domain-containing protein 18A (ANKRD18A), Src, and Nuclear factor (erythroid-derived 2)-like 2 (NRF2), especially decreasing NRF2 nuclear retention and transcriptional activity. …"

Continuing evolution of H5N1 highly pathogenic avian influenza viruses of clade 2.3.2.1a G2 genotype in domestic poultry of Bangladesh during 2018–2021 حسب Mohammed Nooruzzaman (3175290)

"…Consequently, antigenic analysis revealed a significant loss of cross-reactivity between viruses from different host species and periods. …"